CDK5 and non-small cell lung carcinoma: Taken above, aberrant activation of CDK5 might be able to limit the tumor suppressing effect of BIN1 by blocking the BIN1/c-MYC interaction, consequently, overcoming the overexpression of CDK5 might further improve the prognosis of NSCLC patients.